A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Study identifier:D6470C00001

ClinicalTrials.gov identifier:NCT02512575

EudraCT identifier:2015-002002-37

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.

Medical condition

Safety, Healthy subjects, Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD9567 Monohydrat, Placebo oral suspension/ Placebo capsule, Prednisolone

Sex

Male

Actual Enrollment

72

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 18 Nov 2015
Primary Completion Date: 26 Sept 2016
Study Completion Date: 26 Sept 2016

Study design

Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Sept 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria